Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444420 | 1.00 | USP2 (0.51) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL5288704 | 1.00 | USP2 (0.51) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL22034145 | 0.92 | MAPT (0.48) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL28029440 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL28029434 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL1919855 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL10172566 | 0.87 | USP2 (0.53) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL8904969 | 0.87 | USP2 (0.53) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL10172553 | 0.87 | USP2 (0.53) | USP2SMN1; SMN2RECQLEPHA2NR1H2 | |
| SCHEMBL304803 | 0.87 | USP2 (0.53) | USP2SMN1; SMN2RECQLEPHA2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| WO-2025133334-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2025-06-26 | — | — | WO | disclosed |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| EP-4327814-A2 | MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-114380825-B | Substituted pyrazole condensed ring derivative and preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-2920166-B1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2920166-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Array Biopharma, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006715-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | USP2 3655/4885SMN1; SMN2 646/4885RECQL 627/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | USP2 4/4885SMN1; SMN2 2350/4885RECQL 2281/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | USP2 3156/4885SMN1; SMN2 4032/4885RECQL 3331/4885 |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MAN2A1, MAN2B2, MGAT3 | USP2 3321/4885SMN1; SMN2 3045/4885RECQL 2016/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | USP2 4/4885SMN1; SMN2 2139/4885RECQL 1632/4885 |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | USP2 3575/4885SMN1; SMN2 833/4885RECQL 835/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | USP2 3655/4885SMN1; SMN2 646/4885RECQL 627/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | USP2 3655/4885SMN1; SMN2 646/4885RECQL 627/4885 |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | USP2 1757/4885SMN1; SMN2 2313/4885RECQL 1434/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | USP2 3575/4885SMN1; SMN2 833/4885RECQL 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.